Home › Funds › ADAR1 Capital Management, LLC › CLDX
ADAR1 Capital Management, LLC position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
ADAR1 Capital Management, LLC reported holding 799,304 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$25.9M, representing 1.42% of its reported portfolio and ranking #11 among its reported holdings. ADAR1 Capital Management, LLC has disclosed CLDX holdings in 9 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's CLDX position evolved
ADAR1 Capital Management, LLC first disclosed a stake in CLDX in Q2 2024 at 303 shares (US$11K). The position peaked in Q3 2026 at 799,304 shares, worth US$25.9M. Across 9 filings, ADAR1 Capital Management, LLC increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 799,304 shares valued at US$25.9M — an increase of 179,762 shares quarter over quarter.. Notable position changes include a 1550% increase in Q3 2024 (shares fell 26% over the following quarter), a 294% increase in Q2 2025 (shares rose 27% over the following quarter), a 491% increase in Q4 2025 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 303 | $11.21K | New |
| Q3 2024 | 5.00K | $169.95K | Add |
| Q1 2025 | 14.60K | $264.99K | New |
| Q2 2025 | 57.47K | $1.17M | Add |
| Q3 2025 | 109.44K | $2.83M | Add |
| Q4 2025 | 646.77K | $17.57M | Add |
| Q1 2026 | 427.82K | $13.57M | Reduce |
| Q2 2026 | 619.54K | $23.05M | Add |
| Q3 2026 | 799.30K | $25.91M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 39 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$164.2M), Deep Track Capital, LP (US$68.9M), EVENTIDE ASSET MANAGEMENT, LLC (US$61.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.07M sh · $164.19M · Q3 2026
- Deep Track Capital, LP 2.13M sh · $68.89M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.90M sh · $61.46M · Q3 2026
- Commodore Capital LP 1.35M sh · $50.23M · Q2 2026
- Bellevue Group AG 1.20M sh · $44.65M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M sh · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M sh · $38.14M · Q2 2026
- Eversept Partners, LP 1.17M sh · $38.07M · Q3 2026
- Affinity Asset Advisors, LLC 1.16M sh · $37.61M · Q3 2026
- Elmind Capital, LP 990.00K sh · $36.84M · Q2 2026
- Foresite Capital Management VI LLC 879.71K sh · $32.73M · Q2 2026
- Trails Edge Capital Partners, LP 765.00K sh · $24.79M · Q3 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held CLDX?
ADAR1 Capital Management, LLC has disclosed CLDX holdings in 9 of the last 10 reported quarters, going back to Q2 2024.
What is ADAR1 Capital Management, LLC's current position in CLDX?
As of Q3 2026, ADAR1 Capital Management, LLC holds 799.30K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $25.91M, representing 1.42% of its reported portfolio and ranking #11.
Has ADAR1 Capital Management, LLC been buying or selling CLDX?
In the latest 13F filing (Q3 2026), ADAR1 Capital Management, LLC increased its position in CLDX. The position peaked in Q3 2026 at 799.30K shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, EVENTIDE ASSET MANAGEMENT, LLC, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.